Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$137.51M, compared with -$67.64M a year earlier.
Context
- Retained earnings amounted to 139.5% of total assets at the end of Q1 FY2026, up 96.4 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -103.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (115.92M) USD
- Year-over-year change
- -98.7%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (115.92M) | -98.7% |
| FY2024 | 2024-12-31 | (58.33M) | -54.6% |
| FY2023 | 2023-12-31 | (37.74M) | -23.6% |
| FY2022 | 2022-12-31 | (30.53M) | — |
Retained Earnings vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 retained earnings of -$137.51M is the highest of the 11 companies compared; the peer median is -$467.3M.
- Its year-over-year change of -103.3% is the lowest of 11, against a peer median of -20.5%.
- Retained earnings amounts to 139.5% of total assets for AARD, versus a peer median of 325.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$137.51M | -103.3% | — | 139.5% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | -$182.83M | -32.7% | — | 125.4% |
ZURAZura Bio Limited | Mar 2026 | -$248.77M | -43.5% | — | 108.8% |
| Mar 2026 | -$346.72M | -19.7% | — | 195.0% | |
| Mar 2026 | -$429.96M | -16.8% | — | 136.6% | |
| Mar 2026 | -$466.45M | -21.2% | — | 725.4% | |
| Mar 2026 | -$468.15M | -22.1% | — | 468.7% | |
| Mar 2026 | -$621.6M | -27.3% | — | 417.2% | |
| Mar 2026 | -$624.28M | -15.3% | — | 462.2% | |
| Mar 2026 | -$652.34M | -13.1% | — | 293.6% | |
| Mar 2026 | -$841.13M | -0.8% | — | 357.2% | |
| Peer median (excluding AARD) | -$467.3M | -20.5% | — | 325.4% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.